Your browser is no longer supported. Please, upgrade your browser.
DMAC [NASD]
DiaMedica Therapeutics Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own1.20% Shs Outstand18.77M Perf Week-28.39%
Market Cap127.29M Forward P/E- EPS next Y-1.49 Insider Trans12.44% Shs Float17.46M Perf Month-26.68%
Income-13.50M PEG- EPS next Q-0.21 Inst Own34.90% Short Float0.94% Perf Quarter-26.12%
Sales- P/S- EPS this Y11.80% Inst Trans0.31% Short Ratio1.41 Perf Half Y60.95%
Book/sh1.23 P/B5.50 EPS next Y-66.30% ROA-56.00% Target Price- Perf Year64.51%
Cash/sh1.24 P/C5.44 EPS next 5Y30.00% ROE-59.80% 52W Range3.24 - 10.88 Perf YTD-33.33%
Dividend- P/FCF- EPS past 5Y-12.30% ROI- 52W High-37.96% Beta2.48
Dividend %- Quick Ratio20.50 Sales past 5Y- Gross Margin- 52W Low108.14% ATR0.60
Employees11 Current Ratio20.50 Sales Q/Q- Oper. Margin- RSI (14)21.91 Volatility11.52% 6.32%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.30% Profit Margin- Rel Volume1.82 Prev Close6.76
ShortableYes LT Debt/Eq0.00 EarningsMay 05 AMC Payout- Avg Volume116.28K Price6.75
Recom1.70 SMA20-25.61% SMA50-27.31% SMA200-4.20% Volume72,104 Change-0.15%
Apr-09-21Initiated Oppenheimer Outperform $27
Feb-17-21Initiated ROTH Capital Buy $38
Oct-30-20Initiated Guggenheim Buy $16
Jul-08-20Initiated Maxim Group Buy $14
Apr-30-19Initiated Dougherty & Company Buy $8
Mar-05-19Initiated Lake Street Buy $9
May-06-21 06:15AM  
May-05-21 04:28PM  
Apr-28-21 04:04PM  
Apr-22-21 08:16AM  
Apr-20-21 09:25AM  
Apr-05-21 08:14AM  
Mar-27-21 05:30AM  
Mar-11-21 05:15AM  
Mar-10-21 04:04PM  
08:52AM  
Mar-09-21 04:04PM  
Mar-08-21 05:44PM  
Mar-03-21 04:04PM  
Feb-25-21 08:48AM  
Feb-12-21 07:30AM  
Jan-11-21 08:00AM  
Jan-09-21 02:32AM  
Dec-15-20 08:04AM  
Dec-10-20 09:24PM  
08:03AM  
Nov-24-20 09:46AM  
Nov-19-20 09:04AM  
Nov-11-20 08:30AM  
Nov-10-20 11:22AM  
Nov-05-20 06:15AM  
Nov-04-20 04:30PM  
Oct-28-20 08:30AM  
Oct-01-20 03:30PM  
Sep-15-20 08:15AM  
Sep-14-20 09:15AM  
Aug-11-20 04:05PM  
Aug-10-20 04:05PM  
Aug-06-20 04:05PM  
09:05AM  
Aug-05-20 04:01PM  
Jun-10-20 08:16PM  
May-19-20 04:42PM  
May-13-20 04:41PM  
04:40PM  
May-07-20 04:30PM  
Mar-26-20 09:12AM  
Mar-24-20 06:00AM  
Mar-23-20 04:35PM  
Mar-22-20 02:25PM  
Mar-17-20 08:10AM  
Mar-09-20 08:10AM  
Feb-13-20 04:35PM  
Feb-11-20 07:15AM  
Dec-23-19 02:32PM  
Dec-17-19 04:14PM  
Nov-13-19 04:12PM  
Nov-06-19 04:04PM  
Nov-05-19 04:04PM  
Oct-14-19 07:42AM  
Sep-06-19 09:00AM  
Sep-03-19 04:15PM  
Aug-13-19 04:35PM  
Aug-12-19 08:00AM  
Aug-08-19 04:00PM  
Jun-21-19 07:18AM  
Jun-20-19 07:25AM  
Jun-19-19 04:04PM  
May-21-19 08:34AM  
May-14-19 06:00AM  
May-13-19 04:48PM  
May-06-19 08:54AM  
Apr-30-19 04:58PM  
Mar-19-19 04:30PM  
Mar-18-19 01:56PM  
Mar-12-19 01:00PM  
Feb-14-19 08:00AM  
Jan-22-19 07:45AM  
Jan-16-19 04:00PM  
Jan-10-19 08:27AM  
Jan-09-19 05:00PM  
Jan-03-19 10:41AM  
Dec-02-18 05:01PM  
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pilnik Richard D.DirectorDec 04Buy5.3710,00053,69770,846Dec 04 05:46 PM
Giuffre Randall MichaelDirectorNov 20Buy4.2615,00063,912108,588Nov 23 04:22 PM
Kellen ScottCFO and SecretaryNov 09Buy4.192,0008,38712,290Nov 10 08:16 AM